+ All Categories
Home > Documents > 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van...

20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van...

Date post: 22-Dec-2015
Category:
Upload: jonathan-moore
View: 218 times
Download: 3 times
Share this document with a friend
Popular Tags:
46
20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at Robert Schuman University WWW.ULYS.NET [email protected]
Transcript
Page 1: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

20th October 2006

Latest evolutions in “software patents” and “biotech patents”

by

Paul Van den BulckPartner ULYS Law Firm (Brussels-Paris)Lecturer at Robert Schuman University

[email protected]

Page 2: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

I. Introduction

II. Latest evolutions in “software patents”

III. Latest evolutions in “biotech patents”

IV. Interactions EPO/EU/National states

Page 3: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

I. Latest evolutions in « software law »

A.Scope : computer- implemented invention?

• Invention

– whose implementation involves the use of a computer, computer network or other programmable devices

– the invention having one or more features which are realised wholly or partly by means of a computer program.

– But ambiguity : also mere software

Page 4: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

B. Examples

Mobile telephones;

Refrigerators and washing machines

DVD players

Medical imaging (X-ray, NMR)

Anti-lock braking systems (ABS) for cars

Aircraft navigation systems

Etc,..

Mere software ?

Page 5: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

C. International situation

a) Copyright

WIPO copyright treaty December 20, 1996 (art. 4) :

« Computer programs are protected as literary works within the meaning of Article 2 of the Berne Convention. Such protection applies to computer programs, whatever may be the mode or form of their expression. »

1. WIPO

b) Patent

Paris Convention for the Protection of Industrial Property is silent

concerning the protection of softwares by patents

Page 6: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

2. TRIPs agreements (Agreement on Trade-Related Aspects of Intellectual Property Rights)

a) Copyright

Article 10§1 : « Computer programs, whether in source or object code, shall be protected as literary works under the Berne Convention.  »

b) Patent

Article 27.1:

« Subject to the provisions of paragraphs 2 and 3, patents shall be available for any inventions, whether products or processes, in all fields of technology, provided that they are new, involve an inventive step and are capable of industrial application.

(…), patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced.”

Page 7: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

1. Copyright

Directive of 14 May 1991 on the legal protection of computer programs Art 1. : “In accordance with the provisions of this Directive, Member States shall protect computer programs, by copyright, as literary works within the meaning of the Berne Convention for the Protection of Literary and Artistic Works.”

2. Patent

Nothing but … (2002-2005)

D. Community legal framework

Page 8: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

European Patent Office

Non EU institution (Switzerland, Turkey, Croatia, Macedonia, Serbia, etc….)

Inter states body : 31 member states

Grant a “bundle” of national patents

E. “European” framework : EPO

Page 9: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

(1) European patents shall be granted for any inventions which are susceptible of industrial application, which are new and which involve an inventive step.

(2) The following in particular shall not be regarded as inventions within the meaning of paragraph 1 :

(a) discoveries, scientific theories and mathematical methods;

(b) aesthetic creations;

(c) schemes, rules and methods for performing mental acts, playing games or doing business, and programs for computers;

(d) presentations of information.

Patent

European Patent Convention (article 52) :

Page 10: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

(3) The provisions of paragraph 2 shall exclude patentability of the subject-matter or activities referred to in that provision only to the extent to which a European patent application or European patent relates to such subject-matter or activities as such.

Reason of the exclusion of article 52.2 : absence of technical character Indeed

EPC sets out the condition of patentability : novelty, inventive step and industrial application

However no definition of invention (process/product)

Page 11: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

EPO legal tradition : invention should be reserved for technical creations

Technical ?

According to EPO :

the subject matter for which protection is sought must therefore have a technical character, more precisely, involve a “technical teaching”, that is an instruction addressed to a skilled person as to how to solvea particular technical problem (rather than, for example, a purely financial, commercial or mathematical problem) using particular technical means

But is the word “technical” discriminating ?

Page 12: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

Art. 52.3 of EPC : “As such”

The exceptions have to be interpreted narrowly;

therefore : inventions having a technical character that are or may be implemented by computer programs may well be patentable (for ex. ABS)

But quid for mere software ?

Page 13: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

F. Evolution

T 208/84 “VICOM” : the claim directed to a subject-matter for controlling or carrying out a technical process is patentable irrespective of whether it is implemented by hardware or by software

classical doctrine : technical means + non technical means = patentable

The principle = the decision to carry out a technical process by software or other means depends on economic and technological factors

Confirmed by T26/86 “Koch &Sterzel” (X-ray equipment designed for radiological imaging using a computer program)

Page 14: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

T 1173/97 IBM and T 935/97 IBM : new step –software as such-

Claims to computer products (software on a data carrier : CD-Rom, etc…)

Patentable if there is a “further technical effect” (an effect that goes beyond the normal physical effect (for ex. flow of electric current) seen when programs runs

“further technical effect” could be for ex. “more secure operation of the brake of a car”

New doctrine : technical problem/technical solution/non technical means “at all” –software as such-

But may wonder what is patentable : brake or software ?

Page 15: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

G. Comparison with Business methods

As such : not patentable

Decision T258/03 : Method carried out by means of the Internet was denied because there was no technical contribution to the prior art, as the technical implementation of the improved auction rules was done by conventional means of a computer and a computer and a computer network

Conclusion :

Brake : Technical results/technical and no technical means

Computer program : further technical effect (potential technical effects for brake)

Business methods : non technical results/no technical means

So finally what about the “technical teaching” ?

Page 16: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

H. Pending Belgian (European …?) litigation

Page 17: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.
Page 18: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.
Page 19: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

First patent : Method of transferring data being stored in a database

Second : New system and method for performing personalised interactive automated electronic marketing of the marketing service provider

Difference :

“Technical gravy” (formal –not in depth- approach of the claims)

Conclusion : Definition of “technical” to characterized the invention

Page 20: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

II. Latest evolutions in « biotech patent »

Page 21: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

I. General legal framework

Directive 98/44 6th July 1998 on the legal protection of biotechnological inventions (BD).

This directive must be read under the light of others international regulations

Page 22: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

A. Munich convention (EPC):

article 52.4 : Methods for treatment and diagnostic methods practised on the human or animal body shall not be regarded as inventions

article 53.a). : exclusion of inventions contrary to “ordre public” or morality

Page 23: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

B. TRIPS (Trade-Related Aspects of Intellectual Property Rights ) :

In substance idem as EPC : (cf. art. 27 § 2 et 27 § 3) : exclusion methods for treatment and diagnostic methods + contrary to “ordre public” or morality,

But .. patents shall be available for any inventions, whether products or processes, in all fields of technology

Page 24: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

C. CONCIL OF EUROPE’S CONVENTION ON HUMAN RIGHTS AND BIOMEDECINE (1997) :

Art 15 : confirms freedom of research ;

Art 21 : «the human body and its parts shall not, as such, give rise to financial gain ».

Page 25: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

D. UNIVERSAL DECLARATION OF THE HUMAN GENOME AND HUMAN RIGHTS (UNITED NATIONS 11 DECEMBER 1998) :

Art . 11 : Prohibition of « reproductive cloning of human rights »

Art 12. b) : proclaims « freedom of research as part of freedom of thought»

Page 26: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

Permanent tension between the ideas of :

– Freedom of though/research, scientific progress, etc…

and

– Ethical issues (access to health care, cloning, etc…)

The Biotech directive is also a quest to the “right balance»

Page 27: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

II. Reminder : Criteria for granting

art. 52 CBE (novelty, inventive step, industrial application)

Confirm by 3 BD

Page 28: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

EPC sets out the condition of patentability

No definition of « invention »

Scope of invention : technical creations (reason of the exclusions set forth in 52.2 EPC)

the subject matter for which protection is sought must therefore have a technical character, more precisely, involve a “technical teaching”, that is an instruction addressed to a skilled person as to how to solvea particular technical problem (rather than, for example, a purely financial, commercial or mathematical problem) using particular technical means

For Biotech : the human intervention is crucial (no patent when the process is essentially biological : “crossing” or “selection”)

Page 29: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

III. Reminder : Patent of Product/Process

Product : chemical composition, stem cells lines, etc…

Process : method to extract biological material, create a new animal (not variety), etc...

Conclusion : patent of process are more broad

Page 30: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

IV.The directive

A. The principle : articles 3.1 & 3.2

3.1. Usual conditions + “even if they concern : a product consisting of or containing biological material or a process by means of which biological material is produced, processed or

used”

3.2. “Biological material which is isolated from its natural environment or produced by means

of a technical process may be the subject of an invention even if it previously occurred in nature” (invention v. discovery)

Page 31: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

B. Exclusions

Usual exclusionsLife science exclusions“Ordre public” and morality

Page 32: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

1. Usual exclusions

a. Discoveries (art 5.1 BD)

Human body, discovery of one of its elements, sequence of gene

Confirms article 52.2 EPC

But art. 5.2 BD :

« an element isolated from the human body or produced, including the sequence of a gene (…) even if identical to a natural element»

Page 33: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

b. Methods for treatment and diagnostic methods art. 52(4) EPC: 

But 52.4 in fine : exclusion does not apply to products for use in these methods (medicine, imaging device, etc…)

BD confirms

Page 34: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

2. Life science exclusions

a. Plant and animals varieties

Art. 4.1.a. BD

Confirms art 53-b EPC

Art. 5. BD : human body and its elements as such (discovery)

 

b. Biological process

Art. 4.1.b. BD : - Essentially (OK if both) - essentially biological when consists entirely of natural phenomena (crossing, selection,

etc..)

Confirms art. 53-b EPC

Page 35: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

3. “Ordre public” and morality

Art. 6§2 BD :

– processes for cloning human beings;

– processes for modifying the germ line genetic identity of human beings;

– uses of human embryos for industrial or commercial purposes; – processes for modifying the genetic identity of animals which are

likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes.

Page 36: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

Recital 38 : list not exhaustive/criteria = human dignity

Confirms the principle of art 53-a EPC

Page 37: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

C. Examples

What about him : - scope of patentability ? - patentable ?

Page 38: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.
Page 39: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

What about stem cells ?

- Usefulness of stem cells

- Are present in

- Classification

- Sources of embryonic stem cells

- Distinctions

- Cultures of stem cells in laboratory

Page 40: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

Process to extract stem cells/stem cell lines :

patentable ?

Page 41: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

• Article 6(2)c): does the unpatentability concerns:

– an embryo as a whole?; or– every invention concerning stem cells?

No consensus.

• Importance of the interpretation of the concept of “embryo” in the national legislation of the Member States

• Second report 16.c : The Commission has decided not to decide

Page 42: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

‘EDINBURGH PATENT’- case :

Patent granted in December 1999

patent for “isolation, selection and propagation of stem cells of transgenic animals”

EPO Opposition Proceedings (July 2002):

amendment to exclude human embryonic stem cells

adopted broad interpretation of (6(2)c of directive

does this mean that human embryonic stem cells are unpatentable ?

The decision of the Board of Appeal is awaited (end 2006)

Page 43: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

IV. Interactions EPO/EU/National states

Legislation

• Obvious influence of the case law of EPO on the proposition of legislation of the EU :

– Proposition of Directive of software patents/Directive biotech patents

– Harmonisation but also resistance (software : national parliaments/Biotech : differences in implementations)

• Way back of the EU legislation in the EPO Regulation (Directive Biotech patents integrated in the implementing regulation of the EPO)

Page 44: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

Case law

• National jurisdictions are not bind by the decisions of the EPO (grant or maintain)

• National implementation is sometimes different from the EPO case law (Biotech)

• National feelings is sometimes different from the EPO (patent-Netherlands)

• Conclusion : depends on the “culture” of the jurisdiction (resistance-independence, etc…/respect-ignorance, etc..)

• cfr. “Epilady” case

Page 45: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

Institutional limits of the EPO

• Success since more than 30 years must not hide the limits

• Vast majority of technicians and minority of “technicians of the law” in the recourse instance (the questions raised are more and more social and legal and interest the citizens –directive patent software-)

• No “separation of powers” : same institution grant and has jurisdictional power

• And the winner is … ? Directive Community patent v. European patent Litigation agreement (resolution of 12 October 2006 of the European parliament “against” EPLA)

TO BE CONTINUED…..

Page 46: 20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.

QUESTION

S &WWW.ULYS.NET

[email protected]

COMMENTS


Recommended